282 related articles for article (PubMed ID: 19082467)
21. Growth patterns of osteosarcoma predict patient survival.
Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Shin DS; Jeon DG
Arch Orthop Trauma Surg; 2009 Sep; 129(9):1189-96. PubMed ID: 18682966
[TBL] [Abstract][Full Text] [Related]
22. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of fibroblast activation protein and its clinical implications in patients with osteosarcoma.
Yuan D; Liu B; Liu K; Zhu G; Dai Z; Xie Y
J Surg Oncol; 2013 Sep; 108(3):157-62. PubMed ID: 23813624
[TBL] [Abstract][Full Text] [Related]
24. Ephrin A4 expression in osteosarcoma, impact on prognosis, and patient outcome.
Abdou AG; Abd el-Wahed MM; Asaad NY; Samaka RM; Abdallaha R
Indian J Cancer; 2010; 47(1):46-52. PubMed ID: 20071790
[TBL] [Abstract][Full Text] [Related]
25. Vitronectin significantly influences prognosis in osteosarcoma.
Shi K; Lan RL; Tao X; Wu CY; Hong HF; Lin JH
Int J Clin Exp Pathol; 2015; 8(9):11364-71. PubMed ID: 26617861
[TBL] [Abstract][Full Text] [Related]
26. Proliferating cell nuclear antigen index and nm23 expression in osteosarcoma in relation to disease- free survival and tumor grade.
Unal VS; Ayhan A; Tokgozoglu MA
Saudi Med J; 2005 Sep; 26(9):1475-7. PubMed ID: 16155677
[No Abstract] [Full Text] [Related]
27. Expression of matrix metalloproteinase regulator, RECK, and its clinical significance in osteosarcoma.
Xu J; Wu S; Shi X
J Orthop Res; 2010 Dec; 28(12):1621-5. PubMed ID: 20973064
[TBL] [Abstract][Full Text] [Related]
28. Osteosarcoma in Finland from 1971 through 1990: a nationwide study of epidemiology and outcome.
Sampo MM; Tarkkanen M; Kivioja AH; Taskinen MH; Sankila R; Böhling TO
Acta Orthop; 2008 Dec; 79(6):861-6. PubMed ID: 19085506
[TBL] [Abstract][Full Text] [Related]
29. Expression of platelet-derived growth factor-alpha receptor in human osteosarcoma is not a predictor of outcome.
Sulzbacher I; Birner P; Dominkus M; Pichlhofer B; Mazal PR
Pathology; 2010 Dec; 42(7):664-8. PubMed ID: 21080877
[TBL] [Abstract][Full Text] [Related]
30. LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization.
Kresse SH; Ohnstad HO; Paulsen EB; Bjerkehagen B; Szuhai K; Serra M; Schaefer KL; Myklebost O; Meza-Zepeda LA
Genes Chromosomes Cancer; 2009 Aug; 48(8):679-93. PubMed ID: 19441093
[TBL] [Abstract][Full Text] [Related]
31. NPRL2 is an independent prognostic factor of osteosarcoma.
Gao Y; Wang J; Fan G
Cancer Biomark; 2012-2013; 12(1):31-6. PubMed ID: 23321467
[TBL] [Abstract][Full Text] [Related]
32. Expression of hepatocyte growth factor and the proto-oncogenic receptor c-Met in canine osteosarcoma.
Fieten H; Spee B; Ijzer J; Kik MJ; Penning LC; Kirpensteijn J
Vet Pathol; 2009 Sep; 46(5):869-77. PubMed ID: 19429984
[TBL] [Abstract][Full Text] [Related]
33. Three hematological indexes that may serve as prognostic indicators in patients with primary, high-grade, appendicular osteosarcoma.
Hu K; Wang Z; Lin P; Wen Z; Ren H; Sun L; Li H; Li B; Wang S; Zhou X; Tengwang S; Xu L; Ye Z
Oncotarget; 2017 Jun; 8(26):43130-43139. PubMed ID: 28562345
[TBL] [Abstract][Full Text] [Related]
34. Prognostic effect of pathologic fracture in localized osteosarcoma: a cohort/case controlled study at a single institute.
Kim MS; Lee SY; Lee TR; Cho WH; Song WS; Cho SH; Lee JA; Yoo JY; Jung ST; Jeon DG
J Surg Oncol; 2009 Sep; 100(3):233-9. PubMed ID: 19294672
[TBL] [Abstract][Full Text] [Related]
35. Initial tumor size predicts histologic response and survival in localized osteosarcoma patients.
Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jeon DG
J Surg Oncol; 2008 Apr; 97(5):456-61. PubMed ID: 18270971
[TBL] [Abstract][Full Text] [Related]
36. Mitotic arrest defective protein 2 expression abnormality and its clinicopathologic significance in human osteosarcoma.
Yu L; Guo WC; Zhao SH; Tang J; Chen JL
APMIS; 2010 Mar; 118(3):222-9. PubMed ID: 20132188
[TBL] [Abstract][Full Text] [Related]
37. Nrf2 expression is associated with poor outcome in osteosarcoma.
Park JY; Kim YW; Park YK
Pathology; 2012 Dec; 44(7):617-21. PubMed ID: 23172081
[TBL] [Abstract][Full Text] [Related]
38. Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma.
Smida J; Baumhoer D; Rosemann M; Walch A; Bielack S; Poremba C; Remberger K; Korsching E; Scheurlen W; Dierkes C; Burdach S; Jundt G; Atkinson MJ; Nathrath M
Clin Cancer Res; 2010 Aug; 16(16):4256-67. PubMed ID: 20610556
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical profile of ephrin A4 expression in human osteosarcoma.
Abdou AG; Abd El-Wahed MM; Asaad NY; Samaka RM; Abdallaha R
APMIS; 2009 Apr; 117(4):277-85. PubMed ID: 19338516
[TBL] [Abstract][Full Text] [Related]
40. Vasculogenic mimicry: a new prognostic sign of human osteosarcoma.
Ren K; Yao N; Wang G; Tian L; Ma J; Shi X; Zhang L; Zhang J; Zhou X; Zhou G; Wu S; Sun X
Hum Pathol; 2014 Oct; 45(10):2120-9. PubMed ID: 25123071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
